Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantResearch Question:
What is the immediate safety of hyperbaric oxygen therapy prior to allogeneic stem
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS)
who are considered eligible for allogeneic stem cell transplant by the transplant
team at WCI (Wilmot Cancer Institute) will be enrolled in the study. Patients will
receive Melphalan on day -2 and HBO (Hyperbaric Oxygen) therapy on day 0 of the transplant.
After neutrophil recovery is documented, the patients will be seen in clinic at least
weekly through day +100.
Study Reference #: ubmt19163
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Kaitlyn Burrows
Phone: (585) 275-5150
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search